L.J. Altfest & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

L.J. Altfest & Co’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,019	Closed	-$1.51M	–	143
2016 Q3	$1.51M	Hold	5,019	–	–	1%	35
2016 Q2	$1.65M	Buy	+5,019	New	+$273K	1.15%	25

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

L.J. Altfest & Co's MACK Position: Q4 2016 in Review

L.J. Altfest & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 5,019 shares — an estimated $1.51M sold.

L.J. Altfest & Co first reported a position in MACK in Q2 2016 and held it in 2 quarters. The position peaked at $1.65M in Q2 2016. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

L.J. Altfest & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
L.J. Altfest & Co sold 5,019 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.51M.
L.J. Altfest & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
L.J. Altfest & Co's Merrimack Pharmaceuticals, Inc. position peaked at $1.65M in Q2 2016.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on L.J. Altfest & Co's 13F filing for Q4 2016, filed 9 Jan 2017.